Portal de Periódicos da CAPES

The influence of different intensity of treatment on hormonal markers of gonadal function in acute lymphoblastic leukemia survivors

2020; Bioscientifica; Linguagem: Inglês

10.1530/ey.17.9.3

1662-4009

Maryna Krawczuk‐Rybak, Marcin Płonowski, Elżbieta Leszczyńska, Eryk Latoch, Małgorzata Sawicka‐Żukowska, Katarzyna Muszyńska‐Rosłan, Jolanta Skalska‐Sadowska, Jacek Wachowiak, Dorota Sga‐Pondel, Bernarda Kazanowska, Alicja Chybicka, Teresa Stachowicz‐Stencel, Joanna Stefanowicz, Iwona Malinowska, Michał Matysiak, Andrzej Kotan, Mariusz Wysocki, Pobudejska-Piena ̧żek A, Tomasz Szczepański, Borys Przybyszewski, Wanda Badowska, Dorota Szymańska‐Miller, Kowalczyk JR, Elżbieta Kamieńska, Tomasz Urasiński, A. Wawrzenczyk, Beata Żelazowska‐Rutkowska, Bogdan Cylwik,

Childhood Cancer Survivors' Quality of Life

Acute lymphoblastic leukaemia (ALL) is the most common childhood neoplasia with an actual survival rate >80%. ALL treatment has changed considerably during last 30 years; radiotherapy with 24 Gy to the central nervous system (CNS) has been eliminated or reduced to lower doses (12 or 18 Gy) and chemotherapy regimens are now tailored to the specific disease risk. For these reasons, ALL survivors are usually considered to have a low risk of gonadotoxicity. In BFM (Berlin-Frankfurt-Munster) protocols, used in most European countries, patients are stratified into 3 risk groups: standard risk (SR), intermediate risk (IR), and high risk (HR), according to age at diagnosis, initial leucocyte count, immunophenotype of leukaemic blasts, their genetic abnormalities, and response to treatment. The total doses of chemotherapy and the use of cranial irradiation differ among the risk groups and so the impact of late toxicity can be different.